Merck & Co., Inc. (MRK) to Release Quarterly Earnings on Thursday

Merck & Co., Inc. (NYSE:MRK) will be issuing its quarterly earnings data after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of $1.77 per share for the quarter. Merck & Co., Inc. has set its FY 2024 guidance at 7.940-8.040 EPS and its FY24 guidance at $7.94-$8.04 EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, July 30th. The company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.12. Merck & Co., Inc. had a net margin of 21.99% and a return on equity of 40.69%. The business had revenue of $16.10 billion for the quarter, compared to analyst estimates of $15.87 billion. During the same quarter last year, the firm earned ($2.06) EPS. Merck & Co., Inc.’s quarterly revenue was up 7.1% compared to the same quarter last year. On average, analysts expect Merck & Co., Inc. to post $8 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Merck & Co., Inc. Stock Down 0.2 %

Merck & Co., Inc. stock opened at $106.38 on Thursday. The company’s 50 day simple moving average is $113.86 and its 200 day simple moving average is $121.93. Merck & Co., Inc. has a fifty-two week low of $99.80 and a fifty-two week high of $134.63. The firm has a market capitalization of $269.44 billion, a price-to-earnings ratio of 118.20, a PEG ratio of 1.55 and a beta of 0.39. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.47 and a quick ratio of 1.22.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Truist Financial cut their price target on shares of Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price objective on shares of Merck & Co., Inc. in a report on Thursday, October 3rd. Wolfe Research upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, July 31st. Evercore ISI upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Tuesday, July 30th. Finally, Sanford C. Bernstein assumed coverage on shares of Merck & Co., Inc. in a report on Thursday, October 17th. They issued a “market perform” rating and a $115.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating, nine have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $131.62.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.